Genomic profiling for non-small cell lung cancer: Clinical relevance in staging and prognosis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
24 Nov 2023
24 Nov 2023
Historique:
medline:
29
11
2023
pubmed:
28
11
2023
entrez:
28
11
2023
Statut:
ppublish
Résumé
Lung cancer is one of the most common cancers prevalent and around 80% of all cases are non-small cell lung cancer (NSCLC). Due to high recurrence rates, the mortality of NSCLC is high. Conventional staging systems allowed risk classification of patients in order to simplify the patient selection for adjuvant chemotherapy. Gene expression analysis has been shown to possess advantage over conventional staging systems in NSCLC in terms of patients risk classification. This article reviews the evidences on the genomic profiling of NSCLC patients into high and low-risk groups based on the expression of genes involved in various proliferative pathways.
Identifiants
pubmed: 38013359
doi: 10.1097/MD.0000000000036003
pii: 00005792-202311240-00103
pmc: PMC10681555
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e36003Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose. Additionally, the authors declare that they do not have any kind of relationship and affiliations with Oncocyte®.
Références
Haan JC, Bhaskaran R, Ellappalayam A, et al. MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients. Genes Chromosomes Cancer. 2022;61:148–60.
BreastNext: gene sequence and deletion/duplication – Clinical test – NIH Genetic Testing Registry (GTR) – NCBI. [cited 2023 October 12]. Available from: https://www.ncbi.nlm.nih.gov/gtr/tests/560506.1/ .
Schaafsma E, Zhang B, Schaafsma M, et al. Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use. Breast Cancer Res. 2021;23:1–11.
Yonover P, Steyaert S, Cohen JJ, et al. Clinical utility study of confirms mdx for prostate cancer in a community urology practice. J Clin Oncol. 2019;37(suppl 7):94–94.
McKiernan JM, Tutrone RF, Donovan MJ, et al. Urine exosome gene expression assay net benefit analysis in a large pooled cohort. J Clin Oncol. 2020;38(suppl 6):287–287.
Shirley M. Epi proColon® for colorectal cancer screening: a profile of its use in the USA. Mol Diagn Ther. 2020;24:497–503.
Gyparaki MT, Basdra EK, Papavassiliou AG. DNA methylation biomarkers as diagnostic and prognostic tools in colorectal cancer. J Mol Med (Berl). 2013;91:1249–56.
Lung cancer statistics | World Cancer Research Fund International. [cited 2023 May 21]. Available from: https://www.wcrf.org/cancer-trends/lung-cancer-statistics/ .
Lung Cancer Basics | American Lung Association. [cited 2023 May 21]. Available from: https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/basics/lung-cancer-types .
Pirker R. Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer. Transl Lung Cancer Res 2014;3:305–10.
Woodard GA, Wang SX, Kratz JR, et al. Adjuvant chemotherapy guided by molecular profiling and improved outcomes in early stage, non-small-cell lung cancer. Clin Lung Cancer. 2018;19:58–64.
Kratz JR, Haro GJ, Cook NR, et al. Incorporation of a molecular prognostic classifier improves conventional non-small cell lung cancer staging. J Thorac Oncol 2019;14:1223–32.
TNM staging for lung cancer | Cancer Research UK. [cited 2023 May 21]. Available from: https://www.cancerresearchuk.org/about-cancer/lung-cancer/stages-types-grades/tnm-staging .
Yang L, Wang S, Zhou Y, et al. Evaluation of the 7th and 8th editions of the AJCC/UICC TNM staging systems for lung cancer in a large North American cohort. Oncotarget 2017;8:66784–95.
Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2017;12:1109–21.
Choi HS, Jeong BK, Jeong H, et al. Application of the new 8th TNM staging system for non-small cell lung cancer: Treated with curative concurrent chemoradiotherapy. Radiat Oncol. 2017;12:1–8.
Kratz JR, Van Den Eeden SK, He J, et al. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors. JAMA. 2012;308:1629–31.
Kratz JR, Tham PT, Mulvihill MS, et al. Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer. Diagn Mol Pathol. 2013;22:65–9.
Subramanian J, Simon R. Gene expression–based prognostic signatures in lung cancer: ready for clinical use? JNCI J Natl Cancer Inst 2010;102:464.
Kratz JR, Jablons DM. Genomic prognostic models in early-stage lung cancer. Clin Lung Cancer. 2009;10:151–7.
DetermaRx For Oncologists | Oncocyte. [cited 2023 January 9]. Available from: https://oncocyte.com/products/oncologists/ .
Oncocyte Nets $3M VA Contract for DetermaRx Lung Cancer Prognostic Test | Precision Oncology News. [cited 2023 January 9]. Available from: https://www.precisiononcologynews.com/molecular-diagnostics/oncocyte-nets-3m-va-contract-determarx-lung-cancer-prognostic-test#.Y7xIrHZBzIU .
Jiang Y, Lin Y, Fu W, et al. The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non-small cell lung cancer with sensitive EGFR mutations. eClinicalMedicine 2023;64:102205.
Gray JE, Okamoto I, Sriuranpong V, et al. Tissue and plasma EGFR mutation analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non–small cell lung cancer. Clin Cancer Res. 2019;25:6644–52.
Kratz JR, He J, Van Den Eeden SK, et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 2012;379:823–32.
Woodard GA, Gubens MA, Jahan TM, et al. Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer. Clin Lung Cancer. 2014;15:426–32.
Dormady S, Broder MS, Putcha GV, et al. The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer. Int J Clin Oncol. 2015;20:59–69.
Oncocyte Announces New Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting Demonstrating That the DetermaIO TM Gene Expression Test May Predict Response to Immunotherapy in Triple Negative Breast Cancer. [cited 2023 January 9]. Available from: https://edition.cnn.com/business/newsfeeds/globenewswire/7920314.html .
Unger JM, Gralow JR, Albain KS, et al. The use of superlatives in cancer research. JAMA Oncol 2016;2:139–41.
Kratz JR, Van Den Eeden SK, He J, et al. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors. JAMA. 2012;308:1629–31.